Vitamin D for treatment of non-alcoholic fatty liver disease detected by transient elastography: A randomized, double-blind, placebo-controlled trial.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc in the context of fatty liver & elevated liver enzymes.

To evaluate the effects of vitamin D on transient elastography (TE, FibroScan) indices of liver steatosis (controlled attenuation parameter [CAP]) and fibrosis (liver stiffness measurement [LSM]) in adults with non-alcoholic fatty liver disease (NAFLD).

Who Took Part

By PubMed's age tags, the people studied were adults.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

Neither the participants nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.

What Was Measured

PubMed files the paper under topics including Elasticity Imaging Techniques, Liver, Liver Cirrhosis, Non-alcoholic Fatty Liver Disease, Uric Acid and Vitamin D.

Author keywords: elastography and treatment.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in people with fatty liver & elevated liver enzymes.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2020 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, Fatty liver & elevated liver enzymes research.